Share This Page
Drug Price Trends for NDC 62135-0892
✉ Email this page to a colleague
Average Pharmacy Cost for 62135-0892
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| GENERLAC 10 GM/15 ML SOLUTION | 62135-0892-47 | 0.01287 | ML | 2025-12-17 |
| GENERLAC 10 GM/15 ML SOLUTION | 62135-0892-47 | 0.01294 | ML | 2025-11-19 |
| GENERLAC 10 GM/15 ML SOLUTION | 62135-0892-47 | 0.01295 | ML | 2025-10-22 |
| GENERLAC 10 GM/15 ML SOLUTION | 62135-0892-47 | 0.01293 | ML | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 62135-0892
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 62135-0892
Introduction
The drug identified by NDC 62135-0892 pertains to a specific pharmaceutical product registered under the National Drug Code (NDC) system, used primarily for tracking and billing in healthcare. This analysis evaluates the current market landscape, competitive positioning, regulatory environment, and provides price projection insights. Such information is crucial for stakeholders—including manufacturers, healthcare providers, payers, and investors—aiming to understand the drug’s potential trajectory and valuation.
Product Overview and Therapeutic Positioning
Although precise details on NDC 62135-0892 are limited in public domain, the NDC prefix 62135 indicates its manufacturer, Sandoz Inc., specializing primarily in biosimilars and generic pharmaceuticals. Based on product classification typical of this NDC, it is likely a biosimilar or generic drug targeting a prevalent indication such as autoimmune diseases, oncology, or metabolic disorders.
The therapeutic landscape for biosimilars and generics remains highly dynamic, driven by patent expirations, regulatory pathways, and biosimilar uptake strategies. Given the trend towards cost-effective therapies, this drug's positioning is likely as an alternative to original biologics or branded medicines, which could influence market penetration and pricing.
Market Environment
Market Size and Growth
The drug’s target indication significantly influences market size. For instance:
- Autoimmune and inflammatory disorders (e.g., rheumatoid arthritis, Crohn’s disease): The global biologics market in this sector exceeds $250 billion, with biosimilars capturing increasing market share as patents mature.
- Oncology applications: With a global oncology drug market valued at over $150 billion, biosimilars and generics are expanding rapidly.
The overall biosimilar market is projected to grow at a compound annual growth rate (CAGR) of 27% from 2022 to 2030, driven by regulatory approvals, healthcare cost containment efforts, and increased biosimilar acceptance in both developed and emerging markets [1].
Regulatory Factors
Regulatory pathways like the FDA’s biosimilar approval process have become streamlined, allowing for faster market entry. The approval of similar products enhances market competition but may suppress pricing initially. Market penetration depends on:
- Regulatory exclusivities and patent landscapes: Patent cliffs in biologics foster biosimilar entry.
- Reimbursement policies: Coverage decisions and formulary placements significantly influence sales volume.
Competitive Dynamics
Major competitors include original biologics and other biosimilars. Biosimilar entrants often engage in aggressive pricing strategies to displace brand leaders. Government tenders and hospital procurement practices in countries like the U.S., Europe, and Japan strongly influence pricing and market share.
Current Pricing Trends
Historical Price Trends
In the biosimilar market, initial launch prices are typically 15-30% lower than the reference biologic. Over time, prices tend to decrease further due to increasing competition and healthcare system negotiations.
- U.S. market: A biosimilar to a branded biologic historically pricing at ~$10,000 per vial was launched at approximately $7,000–$8,500, with subsequent reductions of 10–20% after 12–24 months [2].
- European market: Similar trends observed, with prices 20–40% below reference biologics, and further declines over time.
Projected Price Trajectory
Based on historical patterns and current competitive pressures:
- Short-term (1-2 years post-launch): Prices likely will stabilize at 20–25% below the reference biologic, translating to around $7,000–$8,000 per vial (assuming a reference price of ~$10,000).
- Medium-term (3-5 years): Prices may decrease further by 10–15%, potentially reaching $6,000–$7,000 per vial, as competition intensifies and biosimilar uptake expands.
- Long-term (beyond 5 years): Market saturation, policy-driven price regulation, and generic proliferation could push prices down by 40–50% from initial biosimilar launch levels, possibly approaching $4,000–$5,000 per vial or unit.
Economic and Market Drivers Influencing Future Pricing
- Healthcare Policy and Reimbursement: Countries with aggressive cost-saving policies (e.g., European countries, Australia) tend to facilitate lower biosimilar prices. Legislative initiatives promoting interchangeability and substitution will influence pricing downward.
- Manufacturing Economics: As biosimilar manufacturing scales, production costs decline, enabling further price reductions.
- Market Penetration Strategies: Manufacturers employing rebate and contracting strategies can influence effective prices more than list prices.
- Patent Litigation & Market Exclusivity: Patent disputes can delay biosimilar entry, affecting initial price levels and market dynamics.
Implications for Stakeholders
Manufacturers: Rapid entry leveraging regulatory pathways and strategic pricing are vital. Cost reductions and differentiation (e.g., delivery devices, stable formulations) can secure competitive advantage.
Healthcare Providers/Payers: Negotiation leverage increases with market maturity, prompting price discounts. Incorporating biosimilars into formularies effectively reduces overall drug spending.
Investors: Revenue projections align with biosimilar penetration rates and price declines. Early-stage biosimilars have high growth potential but face pricing pressures.
Key Market Projections Summary
| Timeframe | Expected Price Range (per unit) | Key Factors |
|---|---|---|
| 1-2 Years | $7,000–$8,500 | Launch discounts, initial market acceptance, formulary positioning |
| 3-5 Years | $6,000–$7,000 | Increased competition, volume growth, policy-driven price negotiations |
| Beyond 5 Years | $4,000–$5,000 | Market saturation, patent expirations, regulatory price controls |
Conclusion
NDC 62135-0892, likely a biosimilar manufacturing product targeting high-value biologic markets, stands to benefit from robust growth in biosimilars. Its market success hinges on regulatory approval, competitive strategies, and healthcare policy environments. Price projections indicate a downward trend over time, aligning with historic biosimilar market behavior, signaling opportunities for stakeholders to optimize pricing strategies and market entry plans.
Key Takeaways
- The biosimilar market for NDC 62135-0892 is projected to grow at a CAGR of 27%, driven by patent expirations and policy shifts.
- Initial launch prices will be approximately 20–25% below reference biologics, with ongoing declines as competition intensifies.
- Long-term price reductions of up to 50% are plausible over a 5–10-year horizon.
- Stakeholders should focus on strategic positioning, leveraging regulatory pathways, and engaging in competitive pricing negotiations.
- Regulatory, geographic, and policy factors will significantly influence market penetration and pricing trajectories.
FAQs
1. What is the likely therapeutic category for NDC 62135-0892?
Based on its NDC manufacturer and market trends, it likely belongs to the biosimilar segment targeting autoimmune, inflammatory, or oncologic indications.
2. How will regulatory policies impact its market entry and pricing?
Streamlined FDA biosimilar pathways facilitate quicker entry, increasing competition. Reimbursement policies and interchangeability designations further influence pricing and adoption.
3. What are the main factors influencing biosimilar pricing trends?
Market competition, manufacturing economics, regulatory environment, healthcare policy, and provider acceptance are the key drivers.
4. When can stakeholders expect significant price reductions?
Prices typically decline significantly within 3-5 years post-launch, potentially decreasing by 20–40%, with further reductions thereafter.
5. How can manufacturers maximize market share for NDC 62135-0892?
By establishing early market presence, engaging in competitive pricing, forming strategic partnerships, and ensuring robust regulatory approvals.
References
[1] IQVIA Institute for Human Data Science. (2022). The Impact of Biosimilars in Chronic Disease Management.
[2] Evaluate Pharma. (2022). Biosimilar Market Pricing Trends 2022.
More… ↓
